[{"address1": "4300 El Camino Real", "address2": "Suite 210", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 351 4495", "website": "https://unicycive.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pramod  Gupta Ph.D.", "age": 63, "title": "Executive Vice President of Pharmaceutical & Business Operations", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 675000, "exercisedValue": 0, "unexercisedValue": 40969}, {"maxAge": 1, "name": "Mr. Douglas  Jermasek M.B.A.", "age": 61, "title": "Executive Vice President of Corporate Strategy", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 412500, "exercisedValue": 0, "unexercisedValue": 42029}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.22, "open": 1.25, "dayLow": 1.085, "dayHigh": 1.2525, "regularMarketPreviousClose": 1.22, "regularMarketOpen": 1.25, "regularMarketDayLow": 1.085, "regularMarketDayHigh": 1.2525, "beta": 2.648, "forwardPE": -2.488889, "volume": 517235, "regularMarketVolume": 517235, "averageVolume": 424462, "averageVolume10days": 538270, "averageDailyVolume10Day": 538270, "bid": 1.1, "ask": 1.13, "bidSize": 500, "askSize": 400, "marketCap": 38927168, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 1.823, "priceToSalesTrailing12Months": 57.66988, "fiftyDayAverage": 1.3674, "twoHundredDayAverage": 0.949505, "currency": "USD", "enterpriseValue": 30019208, "floatShares": 15333149, "sharesOutstanding": 34756400, "sharesShort": 382933, "sharesShortPriorMonth": 56726, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.011, "heldPercentInsiders": 0.18402, "heldPercentInstitutions": 0.51796, "shortRatio": 1.11, "shortPercentOfFloat": 0.0134000005, "impliedSharesOutstanding": 34756400, "bookValue": -0.11, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -31411000, "trailingEps": -1.28, "forwardEps": -0.45, "enterpriseToRevenue": 44.473, "enterpriseToEbitda": -1.446, "52WeekChange": -0.09677422, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "UNCY", "underlyingSymbol": "UNCY", "shortName": "Unicycive Therapeutics, Inc.", "longName": "Unicycive Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626096600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8b289956-33cd-3aa2-beed-9487631afaeb", "messageBoardId": "finmb_605176729", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.12, "targetHighPrice": 9.0, "targetLowPrice": 3.0, "targetMeanPrice": 5.3, "targetMedianPrice": 4.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 9701000, "totalCashPerShare": 0.279, "ebitda": -20765000, "totalDebt": 793000, "quickRatio": 0.553, "currentRatio": 0.764, "totalRevenue": 675000, "revenuePerShare": 0.028, "returnOnAssets": -1.52669, "freeCashflow": 1573000, "operatingCashflow": -18283000, "grossMargins": 1.0, "operatingMargins": -30.776299, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]